Tamoxifen in the treatment of recurrent ovarian carcinoma (Q34072764)

30 July 2017

title

Tamoxifen in the treatment of recurrent ovarian carcinoma (English)

1 reference

30 July 2017

1 reference

1 reference

1

Tropé C

1 reference

30 July 2017

Marth C

2

1 reference

30 July 2017

Kaern J

series ordinal

3

1 reference

30 July 2017

publication date

1 September 2000

1 reference

European Journal of Cancer

30 July 2017

published in

1 reference

30 July 2017

volume

36 Suppl 4

1 reference

30 July 2017

page(s)

S59-61

1 reference

Epithelial ovarian carcinoma

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Estrogen receptor expression is a common feature of ovarian borderline tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Correlation between Steroid Hormone Receptors, Histological and Clinical Parameters in Ovarian Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

A phase II study of tamoxifen in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Tamoxifen therapy in recurrent epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Cyclic hormonal treatment in ovarian cancer. A phase-II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

Tamoxifen in patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900228-8

7 January 2021

10.1016/S0959-8049(00)00228-8

Identifiers

DOI

1 reference

30 July 2017

1 reference